NateraNTRA
NTRA
About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Employees: 4,434
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
286% more first-time investments, than exits
New positions opened: 143 | Existing positions closed: 37
30% more capital invested
Capital invested by funds: $15.3B [Q3] → $19.8B (+$4.52B) [Q4]
21% more funds holding in top 10
Funds holding in top 10: 24 [Q3] → 29 (+5) [Q4]
20% more funds holding
Funds holding: 488 [Q3] → 585 (+97) [Q4]
4.53% more ownership
Funds ownership: 97.2% [Q3] → 101.72% (+4.53%) [Q4]
11% less repeat investments, than reductions
Existing positions increased: 183 | Existing positions reduced: 205
17% less call options, than puts
Call options by funds: $136M | Put options by funds: $163M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$160
12%
upside
Avg. target
$196
38%
upside
High target
$251
76%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Barclays Luke Sergott 28% 1-year accuracy 16 / 57 met price target | 12%upside $160 | Overweight Maintained | 10 Apr 2025 |
RBC Capital Conor McNamara 5% 1-year accuracy 2 / 37 met price target | 76%upside $251 | Outperform Initiated | 13 Mar 2025 |
Morgan Stanley Tejas Savant 21% 1-year accuracy 4 / 19 met price target | 30%upside $185 | Overweight Maintained | 5 Mar 2025 |
Piper Sandler David Westenberg 43% 1-year accuracy 18 / 42 met price target | 44%upside $205 | Overweight Maintained | 4 Mar 2025 |
Canaccord Genuity Kyle Mikson 32% 1-year accuracy 9 / 28 met price target | 37%upside $195 | Buy Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 3 articles about NTRA published over the past 30 days
Positive
Investors Business Daily
4 days ago
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Positive
The Motley Fool
2 weeks ago
27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks
Stanley Druckenmiller is in an elite league of investors that includes the likes of Warren Buffett. He ran his hedge fund firm, Duquesne Capital Management, for 30 years, posting eye-popping average annual returns of 30%.
Neutral
Business Wire
4 weeks ago
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025. DEFINE-HT is the first prospective, multicenter study in heart transplant recipients designed to assess whether elevated levels of donor-derived cell-free DNA (dd-cfDNA), as.
Neutral
The Motley Fool
1 month ago
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
Stanley Druckenmiller, whose net worth is around $6.9 billion, made most of his fortune as a hedge fund manager, and became a well-known name on Wall Street while working for George Soros until 2000.
Positive
Seeking Alpha
1 month ago
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time
Natera Inc. shows robust growth with high margins, a strong genetic testing portfolio, and a recent pullback offering an attractive entry point for investors.
Neutral
Business Wire
1 month ago
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center, phase II trial that explores the discontinuation or de-escalation of anti-HER2 targeted therapy among patients with metastatic HER2+ breast cancer. The trial is supported by funding from the French Ministry of Health through the Hospital Clinical Research Program (PHRC) and.
Neutral
Zacks Investment Research
1 month ago
Natera (NTRA) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Neutral
Business Wire
1 month ago
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA (ctDNA). This builds on Natera's extensive intellectual property estate, including a strong portfolio of molecular residual disease testing (MRD) patents for whole exome and whole genome sequencing. U.S. patent No. 12,203.
Neutral
Seeking Alpha
1 month ago
Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript
Natera, Inc. (NASDAQ:NTRA ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Alexey Aleshin - GM Oncology, CMO Solomon Moshkevich - President, Clinical Diagnostics John Fesko - President and Chief Business Officer Conference Call Participants Doug Schenkel - Wolfe Research Rachel Vatnsdal - JPMorgan Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Catherine Schulte - Baird Daniel Brennan - TD Cowen Dan Leonard - UBS Subbu Nambi - Guggenheim Operator Welcome everyone to Natera's 2024 Fourth Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
1 month ago
Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.64 per share a year ago.
Charts implemented using Lightweight Charts™